Published February 24, 2024
| Version v3
Journal article
Open
DAG1: A Target Enabling Package
Authors/Creators
- 1. Alzheimer's Research UK Oxford Drug Discovery Institute, Centre for Medicines Discovery, University of Oxford, Oxford, United Kingdom
-
2.
Emory University
-
3.
Sage Bionetworks
-
4.
Jackson Laboratory
-
5.
McGill University
Description
Dystroglycan 1 (DAG1) is implicated AD biology based upon its altered expression levels and in late onset Alzheimer's disease (LOAD) and its support role in several aspects of neurobiological function in brain involving neurons, astrocytes and oligodendrocytes (as mapped above and discussed below). The goal of this project is to provide additional research tools for the scientific community to investigate the role of DAG1 in AD pathogenesis--positive or negative--that may shed additional light on basic mechanisms of disease regulation. The aim of this project is to produce TEP reagents to help further understand the biology of DAG1 in Alzheimer’s disease.
Files
TREAT-AD Basic TEP_DAG1_v2_Final.pdf
Files
(974.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:5118e9ac6ea601d5e3b36927f23a2cbd
|
974.6 kB | Preview Download |